ImmunoGen, Inc. Announces Conference Call to Discuss Its Second Quarter Fiscal Year 2010 Financial Results
January 21 2010 - 5:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted anticancer products, today announced that will
host a conference call at 4:30 p.m. ET on Thursday, January
28, 2010 to discuss the Company’s financial results for the
three-month period ended December 31, 2009 – the second quarter of
ImmunoGen’s 2010 fiscal year. Management also will provide an
update on the Company.
To access the live call by phone, dial 913-312-6698. Passcode is
5242531. The call also may be accessed through the Investor
Information section of the Company’s website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through February 4, 2010.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cell-killing agents. The
Company’s Targeted Antibody Payload (TAP) technology uses
antibodies to deliver one of ImmunoGen’s proprietary cell-killing
agents specifically to cancer targets. In addition to the Company’s
product pipeline, compounds utilizing the TAP technology are in
clinical testing through ImmunoGen’s collaborations with Genentech
(a wholly-owned member of the Roche Group), sanofi-aventis, Biogen
Idec and Biotest. The most advanced compound, trastuzumab-DM1
(T-DM1), is in Phase III testing being conducted by Genentech
and Roche. Other ImmunoGen collaborative partners include Bayer
HealthCare and Amgen. More information about ImmunoGen can be found
at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Oct 2023 to Oct 2024